Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORIA phage therapy study in Staphylococcus aureus hip or knee prosthetic joint infection treated with DAIR
NL-OMON58640Phase 2Not yet recruiting
- Sponsor
- Phagenesis
- Start
- Feb 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in periprosthetic joint infection (PJI) comparing PP1815 + DAIR with Placebo + DAIR (2 arms). Primary endpoints: Incidence of serious adverse events and Clinical cure. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
PP1815
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on NL-OMON58640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58640.